OKYO Pharma Limited — News

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company's ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market.

globenewswire.com - 2026-07-28 07:00:00

LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

globenewswire.com - 2026-07-27 07:00:00

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

globenewswire.com - 2026-07-23 12:00:00

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.

globenewswire.com - 2026-07-23 07:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.

globenewswire.com - 2026-07-22 12:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company's ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

globenewswire.com - 2026-07-22 10:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company's ordinary shares on NASDAQ at $1.40 per share.

globenewswire.com - 2026-07-22 07:00:00

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

globenewswire.com - 2026-07-21 09:00:00

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital.

globenewswire.com - 2026-07-21 07:00:00

Market breadth continues to improve, even if it has pulled back lately, according to Adam Turnquist, Chief Technical Strategist for LPL Financial.

proactiveinvestors.com - 2026-07-20 15:31:57

Walt Disney Co (NYSE:DIS, XETRA:WDP) is scheduled to report fiscal third quarter results on August 5, with UBS analysts expecting accelerating earnings...

proactiveinvestors.com - 2026-07-20 12:05:00

OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities and Exchange Commission, while outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said the annual report is available through the SEC and its investor relations website.

proactiveinvestors.com - 2026-07-20 08:44:13

LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC's website and the Company's investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum.

globenewswire.com - 2026-07-20 07:00:00

OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US...

proactiveinvestors.com - 2026-07-20 04:33:00

Delta Air Lines Inc (NYSE:DAL) reaffirmed its full-year earnings outlook despite higher fuel costs, a move Bank of America said underscores the carrier's...

proactiveinvestors.com - 2026-07-13 11:28:00

US banks could deliver broad earnings beats as strong capital markets activity, resilient economic conditions and improving wealth management flows support...

proactiveinvestors.com - 2026-07-13 09:27:00

First Hawaiian, Inc. (NASDAQ:FHB) has agreed to acquire TriCo Bancshares (NASDAQ:TCBK), a combination the bank said will create the leading Pacific banking...

proactiveinvestors.com - 2026-07-13 08:25:00

Taiwan Semiconductor Manufacturing Co (ADR) (NYSE:TSM) reported record June revenue of NT$442.7 billion (about US$13.2 billion), as strong demand for its...

proactiveinvestors.com - 2026-07-13 05:50:00

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company advances urcosimod toward a global Phase 3 pivotal study for neuropathic corneal pain (NCP). Chief executive Robert Dempsey said the FDA's feedback supports a streamlined development strategy that could allow the company to conduct a single-dose Phase 3 study with the potential to serve as a single pivotal trial.

proactiveinvestors.com - 2026-07-11 10:12:29

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing...

proactiveinvestors.com - 2026-07-11 06:00:00

Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational...

proactiveinvestors.com - 2026-07-09 09:26:00

FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new...

proactiveinvestors.com - 2026-07-09 03:19:00

4:15pm: Oil surge pressures Dow, S&P 500 US stocks finished mixed on Wednesday as a jump in oil prices fueled inflation concerns and weighed on investor...

proactiveinvestors.com - 2026-07-08 12:18:00

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from a US Food and Drug Administration Type D meeting that supports advancing its investigational therapy urcosimod into a global Phase 3 pivotal trial for neuropathic corneal pain (NCP). The clinical-stage biotechnology company said the FDA aligned with its proposed single-dose Phase 3 study design and provided feedback that could support a potential single-trial registration pathway, subject to successful study results and continued agency review.

proactiveinvestors.com - 2026-07-08 08:35:41

LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting, validating the Company's regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal trial for NCP.

globenewswire.com - 2026-07-08 07:00:00

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026. Details of the event are as follows: Presenters: Robert J.

globenewswire.com - 2026-07-07 07:00:00

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain.

proactiveinvestors.com - 2026-05-23 08:02:38

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances...

proactiveinvestors.com - 2026-05-23 04:00:00

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-05-20 13:01:23

FTSE 100 up 11 points at 10,335 UK jobs data weakens, unemployment back to 5% IG Group, Diploma, Currys, Dr Martens, SSP, Cranswick among reporters  ...

proactiveinvestors.com - 2026-05-19 12:05:00

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases.

proactiveinvestors.com - 2026-05-19 10:00:32

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO LONDON and NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company's global scientific network with premier European specialists.

globenewswire.com - 2026-05-19 07:00:00

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company...

proactiveinvestors.com - 2026-05-19 05:58:00